Bladder cancer drug combo study halted before enrolling any patients
NCT ID NCT05564416
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study was designed for people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. It aimed to compare a targeted therapy (erdafitinib) alone versus the same drug combined with an immunotherapy (atezolizumab) to see if these treatments could shrink tumors before surgery. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.